Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280490629> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4280490629 endingPage "1988" @default.
- W4280490629 startingPage "1955" @default.
- W4280490629 abstract "This study aims to systematically evaluate the effect of oral Chinese patent medicines on hypertension with network Meta-analysis. Randomized controlled trials on the treatment of hypertension with oral Chinese patent medicine combined with conventional western medicine were retrieved from China National Knowledge Infrastructure(CNKI), Wanfang, VIP, SinoMed, PubMed, EMbase, and Cochrane Library(from establishment of the database to August 2021). Two researchers independently screened the articles, extracted the data, and evaluated article quality. Then R 4.1.0 was employed for data analysis. Finally, 195 eligible articles were screened out, involving 22 546 patients and 18 oral Chinese patent medicines. The results of the network Meta-analysis are as follows. In terms of reducing systolic blood pressure(SBP) and diastolic blood pressure(DBP), Xuesaitong, Qiangli Dingxuan Tablets, Songling Xuemaikang Capsules combined with conventional western medicine are superior. In improving blood lipids, the overall effects of Xinmaitong Capsules, Compound Xueshuantong Capsules, Ginkgo Folium preparations, Yindan Xinnaotong Soft Capsules, and Naoxintong Capsules combined with conventional western medicine are outstanding. In terms of regulating endothelial function, Yindan Xinnaotong Soft Capsules, Xinmaitong Capsules, Zhenju Jiangya Tablets, Compound Danshen Dripping Pills, Xuesaitong with conventional western medicine have certain advantages. As for the safety, the incidence of adverse reactions of conventional western medicine combined with oral Chinese patent medicines is lower than that of conventional western medicine alone. In summary, compared with conventional western medicine alone, the 18 oral Chinese patent medicines combined with conventional western medicine in the treatment of hypertension show advantages in improving blood pressure, blood lipids, and endothelial function. Among them, Xuesaitong, Qiangli Dingxuan Tablets, and Songling Xuemaikang Capsules may be the best oral Chinese patent medicines for lowering blood pressure. The conclusion needs to be further verified by more high-quality studies." @default.
- W4280490629 created "2022-05-22" @default.
- W4280490629 creator A5002972091 @default.
- W4280490629 creator A5004800450 @default.
- W4280490629 creator A5019732521 @default.
- W4280490629 creator A5035429453 @default.
- W4280490629 creator A5052600176 @default.
- W4280490629 creator A5064452315 @default.
- W4280490629 date "2022-04-01" @default.
- W4280490629 modified "2023-09-30" @default.
- W4280490629 title "[Network Meta-analysis of efficacy and safety of oral Chinese patent medicines combined with conventional western medicine in treatment of hypertension]." @default.
- W4280490629 doi "https://doi.org/10.19540/j.cnki.cjcmm.20211223.501" @default.
- W4280490629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35534266" @default.
- W4280490629 hasPublicationYear "2022" @default.
- W4280490629 type Work @default.
- W4280490629 citedByCount "1" @default.
- W4280490629 countsByYear W42804906292023 @default.
- W4280490629 crossrefType "journal-article" @default.
- W4280490629 hasAuthorship W4280490629A5002972091 @default.
- W4280490629 hasAuthorship W4280490629A5004800450 @default.
- W4280490629 hasAuthorship W4280490629A5019732521 @default.
- W4280490629 hasAuthorship W4280490629A5035429453 @default.
- W4280490629 hasAuthorship W4280490629A5052600176 @default.
- W4280490629 hasAuthorship W4280490629A5064452315 @default.
- W4280490629 hasConcept C126322002 @default.
- W4280490629 hasConcept C142724271 @default.
- W4280490629 hasConcept C188947578 @default.
- W4280490629 hasConcept C197934379 @default.
- W4280490629 hasConcept C204787440 @default.
- W4280490629 hasConcept C2776478404 @default.
- W4280490629 hasConcept C2777980684 @default.
- W4280490629 hasConcept C2991693576 @default.
- W4280490629 hasConcept C535046627 @default.
- W4280490629 hasConcept C556039675 @default.
- W4280490629 hasConcept C71924100 @default.
- W4280490629 hasConcept C84393581 @default.
- W4280490629 hasConcept C95190672 @default.
- W4280490629 hasConcept C98274493 @default.
- W4280490629 hasConceptScore W4280490629C126322002 @default.
- W4280490629 hasConceptScore W4280490629C142724271 @default.
- W4280490629 hasConceptScore W4280490629C188947578 @default.
- W4280490629 hasConceptScore W4280490629C197934379 @default.
- W4280490629 hasConceptScore W4280490629C204787440 @default.
- W4280490629 hasConceptScore W4280490629C2776478404 @default.
- W4280490629 hasConceptScore W4280490629C2777980684 @default.
- W4280490629 hasConceptScore W4280490629C2991693576 @default.
- W4280490629 hasConceptScore W4280490629C535046627 @default.
- W4280490629 hasConceptScore W4280490629C556039675 @default.
- W4280490629 hasConceptScore W4280490629C71924100 @default.
- W4280490629 hasConceptScore W4280490629C84393581 @default.
- W4280490629 hasConceptScore W4280490629C95190672 @default.
- W4280490629 hasConceptScore W4280490629C98274493 @default.
- W4280490629 hasIssue "7" @default.
- W4280490629 hasLocation W42804906291 @default.
- W4280490629 hasOpenAccess W4280490629 @default.
- W4280490629 hasPrimaryLocation W42804906291 @default.
- W4280490629 hasRelatedWork W170915 @default.
- W4280490629 hasRelatedWork W170953 @default.
- W4280490629 hasRelatedWork W1899303 @default.
- W4280490629 hasRelatedWork W22706785 @default.
- W4280490629 hasRelatedWork W2359887 @default.
- W4280490629 hasRelatedWork W2507035 @default.
- W4280490629 hasRelatedWork W2611145 @default.
- W4280490629 hasRelatedWork W2677511 @default.
- W4280490629 hasRelatedWork W27489483 @default.
- W4280490629 hasRelatedWork W285006 @default.
- W4280490629 hasVolume "47" @default.
- W4280490629 isParatext "false" @default.
- W4280490629 isRetracted "false" @default.
- W4280490629 workType "article" @default.